23 Jul, 2026
According to Straits Research, the global hematologic malignancies market size was valued at $78.8 billion in 2025 and is projected to grow from $85.22 billion in 2026 to $159.37 billion by 2034, at a CAGR of 8.14% during the forecast period 2026–2034.
Hematologic malignancies are cancers that impact the blood, bone marrow, lymphatic system, and lymph nodes. These cancers are typically classified into two main categories: leukemia, which affects the blood and bone marrow, and lymphoma and myeloma, which affect the lymphatic system and plasma cells, respectively.
These cancers interfere with the normal production and function of blood cells, leading to a range of symptoms, including anemia, increased susceptibility to infections, and bleeding. Treatment options include chemotherapy, targeted therapies, stem cell transplants, and immunotherapy, which aim to control the disease and improve patient survival rates.
Increasing prevalence of hematologic malignancies drives the global market
The rising prevalence of hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma, is a major factor propelling market growth. As the incidence of these cancers increases, so does the demand for advanced diagnostic tools, innovative treatments, and personalized care, which collectively fuel market expansion.
For example, the Leukemia & Lymphoma Society estimates that in 2024, approximately 62,770 people will be diagnosed with leukemia, with an estimated 456,481 individuals currently living with the disease in the U.S. This surge in cases further drives the need for new and improved cancer therapies, contributing to the overall market growth.
Surge in product approvals and advancement in CAR T Cell Therapy creates tremendous opportunities
The surge in product approvals for hematologic malignancies is a significant driver of market growth. Regulatory bodies like the FDA and EMA are expediting the approval process for groundbreaking therapies, including CAR-T cell therapies, monoclonal antibodies, and antibody-drug conjugates. These fast-track approvals incentivize pharmaceutical companies to ramp up research and development, further fueling market expansion.
For example, in March 2024, Bristol Myers Squibb received accelerated FDA approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR-T cell therapy, for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Such approvals not only enhance the company's product portfolio but also contribute significantly to overall market growth.
North America holds a leading position, accounting for a 41% share in 2024 in the hematologic malignancies market due to its well-established healthcare systems and cutting-edge technology, which enable early diagnosis and access to innovative treatments such as CAR-T cell therapy and monoclonal antibodies. The region also benefits from high adoption rates of new therapies and a large patient population.
sales@straitsresearch.com